Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age

Keyphrases

• Meningococcal C Conjugate Vaccine 100%
• Immunogenicity 100%
• MenC 100%
• Titre 66%
• DTwP 66%
• Revaccination 33%
• Diphtheria 33%
• Tetanus 33%
• Concomitant Administration 33%
• Meningococcal Serogroup C 33%
• Oral Polio Vaccine 33%
• Immunogenic 33%
• Whole-cell Pertussis Vaccine 33%
• IgG Levels 33%
• Serum Bactericidal Activity 33%
• Injection Site 33%
• Reactogenicity 33%
• Local Reaction 33%
• Haemophilus Influenzae Type b Vaccine 33%
• Systemic Events 33%
• Production Level 33%
• Manufacturing Scale 33%
• Scale-up Production 33%

Immunology and Microbiology

• Serotype 100%
• Conjugate Vaccine 100%
• Immunogenicity 100%
• Haemophilus Influenzae Type B 50%
• Oral Poliomyelitis Vaccine 50%
• Whole Cell 50%
• Pertussis Vaccine 50%